Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Resistin in rodents and humans.

Park HK, Ahima RS.

Diabetes Metab J. 2013 Dec;37(6):404-14. doi: 10.4093/dmj.2013.37.6.404.

2.

Linking resistin, inflammation, and cardiometabolic diseases.

Park HK, Kwak MK, Kim HJ, Ahima RS.

Korean J Intern Med. 2017 Mar;32(2):239-247. doi: 10.3904/kjim.2016.229. Epub 2017 Feb 16. Review.

3.

Recent advances in the relationship between obesity, inflammation, and insulin resistance.

Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B.

Eur Cytokine Netw. 2006 Mar;17(1):4-12. Review.

4.

Role of resistin in insulin sensitivity in rodents and humans.

Barnes KM, Miner JL.

Curr Protein Pept Sci. 2009 Feb;10(1):96-107. Review.

PMID:
19275676
5.

Resistin's, obesity and insulin resistance: the continuing disconnect between rodents and humans.

Huang X, Yang Z.

J Endocrinol Invest. 2016 Jun;39(6):607-15. doi: 10.1007/s40618-015-0408-2. Epub 2015 Dec 12. Review.

PMID:
26662574
6.

Human resistin: found in translation from mouse to man.

Schwartz DR, Lazar MA.

Trends Endocrinol Metab. 2011 Jul;22(7):259-65. doi: 10.1016/j.tem.2011.03.005. Epub 2011 Apr 15. Review.

7.

Resistin: insulin resistance to malignancy.

Codoñer-Franch P, Alonso-Iglesias E.

Clin Chim Acta. 2015 Jan 1;438:46-54. doi: 10.1016/j.cca.2014.07.043. Epub 2014 Aug 13. Review.

PMID:
25128719
8.

Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.

Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O, Krone W.

Horm Metab Res. 2010 Apr;42(4):268-73. doi: 10.1055/s-0029-1243638. Epub 2010 Jan 20.

PMID:
20091460
9.

Resistin is an inflammatory marker of atherosclerosis in humans.

Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ.

Circulation. 2005 Feb 22;111(7):932-9. Epub 2005 Feb 14.

10.

Adiponectin and resistin--new hormones of white adipose tissue.

Bełtowski J.

Med Sci Monit. 2003 Feb;9(2):RA55-61. Review.

PMID:
12601307
11.

Evidence for the involvement of resistin in inflammation and cardiovascular disease.

Gómez-Ambrosi J, Frühbeck G.

Curr Diabetes Rev. 2005 Aug;1(3):227-34. Review.

PMID:
18220599
12.

The role of resistin in obesity-induced insulin resistance.

Haluzik M, Haluzikova D.

Curr Opin Investig Drugs. 2006 Apr;7(4):306-11. Review.

PMID:
16625816
13.

An inflammatory cascade leading to hyperresistinemia in humans.

Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA.

PLoS Med. 2004 Nov;1(2):e45. Epub 2004 Nov 30. Review.

14.

Human resistin and the RELM of Inflammation in diabesity.

Al Hannan F, Culligan KG.

Diabetol Metab Syndr. 2015 Jun 18;7:54. doi: 10.1186/s13098-015-0050-3. eCollection 2015.

15.

The current biology of resistin.

Steppan CM, Lazar MA.

J Intern Med. 2004 Apr;255(4):439-47. Review.

16.

The role of resistin as a regulator of inflammation: Implications for various human pathologies.

Filková M, Haluzík M, Gay S, Senolt L.

Clin Immunol. 2009 Nov;133(2):157-70. doi: 10.1016/j.clim.2009.07.013. Epub 2009 Sep 8. Review.

PMID:
19740705
17.

Resistin: functional roles and therapeutic considerations for cardiovascular disease.

Jamaluddin MS, Weakley SM, Yao Q, Chen C.

Br J Pharmacol. 2012 Feb;165(3):622-32. doi: 10.1111/j.1476-5381.2011.01369.x. Review.

18.

Role of resistin in inflammation and inflammation-related diseases.

Pang SS, Le YY.

Cell Mol Immunol. 2006 Feb;3(1):29-34. Review.

19.

[Resistin: a pathogenic factor or a biomarker of metabolic disorders and inflammation?].

Karbowska A, Boratyńska M, Klinger M.

Postepy Hig Med Dosw (Online). 2009 Oct 23;63:485-91. Review. Polish.

20.

Resistin as a cardiovascular and atherosclerotic risk factor and uremic toxin.

Cohen G, Hörl WH.

Semin Dial. 2009 Jul-Aug;22(4):373-7. doi: 10.1111/j.1525-139X.2009.00583.x. Review.

PMID:
19708984

Supplemental Content

Support Center